The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Step Edits Associated with IV Iron Therapies
Panelists discuss how increasing insurance step edit requirements for high-dose IV iron formulations have created barriers to optimal patient care, requiring providers to implement strategic prior authorization processes and develop documentation protocols to demonstrate medical necessity while advocating for appropriate patient access to these medications.
Watch
Adherence and Time Spent Receiving IV Iron Infusions
Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and administering IV iron treatments, leading clinicians to favor products that can achieve iron repletion in fewer sessions.
Watch
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
Sugammadex Safe, Effective Post Surgery in Myasthenia Gravis
February 18th 2025Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular blockade from rocuronium bromide or vecuronium bromide.
Read More
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
February 18th 2025Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).
Read More
Challenging Perceptions: Exploring Racial, Ethnic Disparities in Psoriatic Arthritis
February 17th 2025Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.
Watch
Key Structural and Operational Considerations for Biosimilar Adoption
February 17th 2025Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.
Watch
The Role of Private Label Agreements in Enhancing Access to Biosimilars
February 17th 2025Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
Watch
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
February 14th 2025Panelist discusses how HS Centers of Excellence demonstrate potential for enhanced health care delivery through coordinated, specialized care approaches, with managed care organizations driving adoption through strategic incentives and collaborative frameworks.
Watch
Reflections on 2024’s Progress in R/R CLL
February 14th 2025Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.
Watch
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Clinical and Economic Consequences of Nonadherence to IV Iron
Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.
Watch
Clinical Impact of Hypophosphatemia
Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.
Watch